Scientific Reports, 2025 · DOI: https://doi.org/10.1038/s41598-024-82121-3 · Published: January 8, 2025
Spinal cord injury (SCI) can cause permanent loss of motion or sensation. After the initial physical damage, the body responds with inflammation, which paradoxically can worsen the injury. This study focuses on how a protein called SIX1 affects inflammation after SCI in mice. Microglia, which are immune cells in the spinal cord, can either promote (M1) or reduce (M2) inflammation. The researchers found that SIX1 increases after SCI and seems to push microglia towards the M1 type, worsening inflammation. By blocking SIX1, the researchers were able to shift microglia towards the M2 type, reduce inflammation, and improve recovery in mice with SCI. This suggests that targeting SIX1 could be a new way to treat SCI.
SIX1 may represent a novel therapeutic target for treating spinal cord injury by modulating microglia polarization.
SIX1 inhibitors could be developed as potential drugs to improve recovery following SCI.
Targeting the VEGF-C/VEGFR3 axis downstream of SIX1 could also be a strategy to reduce inflammation and promote recovery in SCI.